Demystifying FluMist, a new intranasal, live influenza vaccine

Author and Disclosure Information

ABSTRACTFluMist—a cold-adapted, live-attenuated, trivalent, intranasal influenza virus vaccine approved by the US Food and Drug Administration on June 17, 2003—has been shown to be safe and effective, but its role in the general prevention of influenza is yet to be defined. Intranasal administration is expected to be more acceptable than parenteral, particularly in children, but the potential for the shedding of live virus may pose a risk to anyone with a compromised immune system.


Next Article:

When to wean from a ventilator: An evidence-based strategy

Related Articles